Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial

Fig. 3

Kaplan-Meier survival curves. A Duration of response of 34 responding patients. B PFS of 52 patients. C PFS of patients with versus those without liver metastases. D PFS of patients who received ≥2400 mg nimotuzumab versus those who received <2400 mg nimotuzumab. E PFS of patients at initial diagnosis with EBV DNA ≥10,000 copies/mL versus those with EBV DNA <10,000 copies/mL. F PFS of patients whose EBV DNA declined to zero after 2 cycles versus those whose EBV DNA did not. Abbreviations: DOR, duration of response; EBV, Epstein-Barr virus; HR, hazard ratio; PFS, progression-free survival

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us